CoChat

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden

Open access
Morrison, Carl, Pabla, Sarabjot, Conroy, Jeffrey M., Nesline, Mary K., Glenn, Sean T., Dressman, Devin, Papanicolau-Sengos, Antonios, Burgher, Blake, Andreas, Jonathan, Giamo, Vincent, Qin, Moachun, Wang, Yirong, Lenzo, Felicia L., Omilian, Angela, Bshara, Wiam, Zibelman, Matthew, Ghatalia, Pooja, Dragnev, Konstantin, Shirai, Keisuke, Madden, Katherine G., Tafe, Laura J., Shah, Neel, Kasuganti, Deepa, de la Cruz-Merino, Luis, Araujo, Isabel, Saenger, Yvonne, Bogardus, Margaret, Villalona-Calero, Miguel, Diaz, Zuanel, Day, Roger, Eisenberg, Marcia, Anderson, Steven M., Puzanov, Igor, Galluzzi, Lorenzo, Gardner, Mark, Ernstoff, Marc S. · 2018 · Journal for ImmunoTherapy of Cancer
Cited by 147

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Immune checkpoint inhibitors (ICIs) have changed the clinical management of melanoma. However, not all patients respond, and current biomarkers including PD-L1 and mutational burden show incomplete predictive performance. The clinical validity and utility of complex biomarkers have not been studied in melanoma. METHODS: T-cell infiltration pattern, mutational burden, and 394 immune transcript expression. PD-L1 IHC and mutational burden were assessed for association with overall survival (OS) in 94 patients treated prior to ICI approval by the FDA (historical-controls), and in 137 patients treated with ICIs. Unsupervised analysis revealed distinct immune-clusters with separate response rates. This comprehensive immune profiling data were then integrated to generate a continuous Response Score (RS) based upon response criteria (RECIST v.1.1). RS was developed using a single institution training cohort (n = 48) and subsequently tested in a separate eight institution validation cohort (n = 29) to mimic a real-world clinical scenario. RESULTS: PD-L1 positivity ≥1% correlated with response and OS in ICI-treated patients, but demonstrated limited predictive performance. High mutational burden was associated with response in ICI-treated patients, but not with OS. Comprehensive immune profiling using RS demonstrated higher sensitivity (72.2%) compared to PD-L1 IHC (34.25%) and tumor mutational burden (32.5%), but with similar specificity. CONCLUSIONS: In this study, the response score derived from comprehensive immune profiling in a limited melanoma cohort showed improved predictive performance as compared to PD-L1 IHC and tumor mutational burden.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s40425-018-0344-8

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 147

Metadata

Authors
Morrison, C., Pabla, S., Conroy, J. M., Nesline, M. K., Glenn, S. T., Dressman, D., Papanicolau-Sengos, A., Burgher, B., Andreas, J., Giamo, V., Qin, M., Wang, Y., Lenzo, F. L., Omilian, A., Bshara, W., Zibelman, M., Ghatalia, P., Dragnev, K., Shirai, K., Madden, K. G., Tafe, L. J., Shah, N., Kasuganti, D., de la Cruz-Merino, L., Araujo, I., Saenger, Y., Bogardus, M., Villalona-Calero, M., Diaz, Z., Day, R., Eisenberg, M., Anderson, S. M., Puzanov, I., Galluzzi, L., Gardner, M., & Ernstoff, M. S.
Venue
Journal for ImmunoTherapy of Cancer
Publisher
BMJ
Published
2018-05-09
Volume
6
Issue
1
Pages
32-32
ISSN
2051-1426 (ISSN-L)
OpenAlex
W2806277324
Cited by
147
References
14
FWCI
6.07
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden. https://app.cochat.ai/papers/10.1186/s40425-018-0344-8
The paper
Morrison, C., Pabla, S., Conroy, J. M., Nesline, M. K., Glenn, S. T., Dressman, D., Papanicolau-Sengos, A., Burgher, B., Andreas, J., Giamo, V., Qin, M., Wang, Y., Lenzo, F. L., Omilian, A., Bshara, W., Zibelman, M., Ghatalia, P., Dragnev, K., Shirai, K., . . . Ernstoff, M. S. (2018). Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1186/s40425-018-0344-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.